By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Gradalis Inc. 

2545 Golden Bear Drive
Suite 110
Carrollton  Texas  75006  U.S.A.
Phone: n/a Fax: n/a



Company News
Gradalis Inc. Announces The Appointment Of Sir Marc Feldmann As Chairman Of The Newly Formed Scientific Advisory Board 9/8/2016 8:37:29 AM
Gradalis Inc. Announces Dosing Of First Patient In Pilot Study Combining Vigil Engineered Autologous Tumor Cell Immunotherapy And Durvalumab In Advanced Breast Cancer 8/29/2016 8:39:52 AM
Gradalis Inc. Appoints Martin J. Birkhofer, M.D. Chief Medical Officer 7/26/2016 6:49:12 AM
Gradalis Inc. Announces Presentation Of Data From A Pilot Study Of Vigil Cancer Vaccine In Ewing’s Sarcoma 6/4/2015 7:50:40 AM
Gradalis Inc. Announces Initiation Of A Phase 3 Registration Study For Vigil In Ovarian Cancer 2/26/2015 10:24:35 AM
Gradalis Inc. Announces Presentation Of New Data 6/18/2014 9:09:41 AM
Gradalis Inc. Announces Dr. Scott Gottlieb Joins Board Of Directors 6/4/2014 9:03:30 AM
Gradalis Inc. Announces Appointment of Phillip B. Maples, Ph.D., as Executive Vice President and Chief Technical Officer 8/20/2013 6:14:41 AM
Ex-Prometheus Exec Tapped to Lead Gradalis Inc. 7/23/2013 6:37:53 AM
Gradalis Inc. Release: FANG™ Personalized Tumor Vaccine Stimulates Immune Response and More than Doubles Time to Recurrence in Patients with Advanced Stage Ovarian Cancer 5/16/2013 9:27:33 AM